C) Transplant Infections Program
1. To reduce the incidence of infectious complications.
Line 1. To reduce the incidence of tuberculosis inhepatic transplant.
Action 1
Clinical Trial on the prophylaxis of tuberculosis in hepatic transplant patients, comparing levoflosacin vs isoniazid.
Responsible: Hospital Universitario Reina Sofía. Dra. Elisa Vidal.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 2. To reduce the incidence of pre-surgical infecction.
Action 1
Clinical Trial on the treatment of asymptomatic bacteriuriain renal transplant patient.
Responsible: Hospital Universitario 12 Octubre. Dr. Francisco López. This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Hospital Universitario Bellvitge.
Action 2
Development of clinical practical guide on the management of urinay infection.
Responsible: Hospital Universitario Reina Sofía. Dra. Elisa Vidal.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 3. To reduce the incidence of infections caused by trimetoprime-sulfametoxazol sensitive microorganisms.
Action 1
Study on the efficacy of the prophylaxis with cotrimoxazol in the prevention of pneumonia caused by Pneumocystis jirovecii and Nocardia spp. in solid organ transalnt receiver patients in the cohort RESITRA .
Responsible: Hospital Universitario Reina Sofía. Dra. Elisa Vidal.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
2. To get knowledge on the mortality and to reduce te morbidity of infections with clinical impact on transplant.
Line 1. To get knowledge on the mortality attributable to the main infectious complications.
Action 1
Study in the mortality attributable to the infectious complications in the cohort RESITRA .
Responsible: Hospital Universitario Vall d´Hebron. Dr. Joan Gavaldá Santapau.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 2. Infections caused by multi-resistant bacteria.
Action 1
Development of clinical practice guide and consensus documents on the scientific evidences.
Responsible: Hospital Clinic
Line 3. Invasive fungal infection.
Action 1
Clinical Trial on anifulafungin versus anfotericin B liposomal for the antifungal prophylaxis in hig risk hepatic transplant patients (AVALTRA) .
Responsible: Hospital Clinic
Action 2
Immune response of the host patient in invasive aspergillosis.
Responsible: Hospital Universitario Bellvitge
Line 4. Infections by respiratory virus.
Action 1
Study on the incidence, clinical meaning and prognostic of teh infection caused by respiratory virus in lung transplant.Impact of the respiratory virus infection in the natural history of chronic rejection.
Responsible: Hospital Universitario Vall d´Hebron. Dr. Joan Gavaldá Santapau.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 5. BK virus.
Action 1
Clinical Guide on the management of the infection caused by BK virus in solid organ transplant receivers.
Responsible: Hospital Gregorio Marañón
Line 6. Visceral Leishmaniasis.
Action 1
Study of control cases to characterize the clinical picture and teh risk factors in order to unable early diagnostics and treatment.
Responsible: Hospital Universitario Reina Sofía. Dra. Elisa Vidal.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Line 7. To personalize preventive management of the infection caused by citomegalovirus, to characterize the indirect consequences of the infection and better knwe the resistance of the virus to ganciclovir.
Action 1
Characterization of the risk of CMV replication based on the study of the immunological CMV pre-transplant.
Responsible: Hospital Universitario Reina Sofía. Dr. Julián de la Torre.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Hospital Clinic
Action 2
Utility os the immunologic monitorization of sero-positiv receptors.
Responsible: Hospital Universitario Virgen del Rocío. Dr. Pilar Pérez. This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Hospital Universitario 12 de Octubre. Dr. Mario Fernández
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 3
Clinical Trial o the prophylaxis of the CMV caused disease in high-risk (D+R-) patients, comparing the administration of ganciclovir since the day 0 port-transplant with the one initiated on day 15 post-transplant.
Responsible: Hospital Universitario 12 de Octubre. Dr. Rafael San Juan.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 4
Revision 2010 of the consensus document on the management of the CMV caused infection in solid organ transplant in the year 2005.
Responsible: Hospital Universitario Reina Sofía. Dr. Julián de la Torre.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 5
To characterize the indirect consequencies of the CMV caused infection. Effect of the CMV replication on the development of immune senescence.
Responsible: Hospital Universitario Reina Sofía. Dr. Julián de la Torre.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Action 6
To know the incidence of resistance of citomegalovirus to ganciclovir.
Responsible: Hospital Vall d´Hebron. Dr. Joan Gavaldá Santapau. This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
